Toxicities Associated with CAR T-Cell Therapy — An Interview with Dr Matthew Lunning
Hematologic Oncology Update
00:00
Managing discharge and post‑CAR T monitoring
Dr Lunning explains conservative return-to-driving and monitoring timelines, especially after neurotoxicity and distance considerations.
Play episode from 39:55
Transcript
